Table I.

Previous studies on gonadotropin treatment during minipuberty

Reference	Treatment	Patient	Diagnosis	Crypt-orchidism	Micro-penis	Age (mo)	Treatment duration (mo)	Before treatment		During/after treatment (highest value)
								Inh-B (ng/L)	TV (mL)	Inh-B (ng/L)	TV (mL)
Main et al. (2002)	FSH 21.3 IU x2/week, LH 20–40 IU x2/week, T suppositories 1 mg/day	1	CHH	No	Yes	7.9	FSH 6, LH 3.5, T 1.5	121	0.3	268a	0.8
Bougnères et al. (2008)	FSH 67–125 IU daily, LH 50–56 IU daily	1	CPHD	No	Yes	1.9	4	167 (32)b	0.6	701 (284)b	2.1
		2	CHH	No	Yes	4.7	7	48 (9)b	0.5	426 (189)b	2.1
Sarfati et al. (2015)	FSH 75 IU daily, LH 75 IU daily	1	CHH	No	Yes	1	6	24	0.3	NA	2.3
Lambert and Bougneres (2016)c	FSH 75–150 daily, LH 50 daily	1	CPHD	Yes	Yes	6	6	5	NA	55	0.6
		2	CPHD	Yes	Yes	11	6	100	NA	505	2.0
		3	CPHD	Yes	NA	10	6	155	NA	544	2.1
		4	CHH	Yes	Yes	4.5	6.5	91	NA	111	0.8
		5	CHH	Yes	Yes	2.5	6.5	73	NA	401	0.7
		6	CHH	Yes	Yes	9	5	5	NA	287	1.2
		7	CHH	Yes	NA	5	5	64	NA	514	0.9
		8	CHH	Yes	Yes	0.25	6	14	NA	530	2.0
Stoupa et al. (2017)	FSH 75 daily, LH 75–150 dailyd	1	CHH	Yes	Yes	4.5	6	95 (75)e	0.7 (SD not reported)e	469 (283)e	2.2 (SD not reported)e
		2	CPHD	No	Yes	5.5	3
		3	CHH	Yes	Yes	4.5	4
		4	CHH	Yes	Yes	3	3
		5	CHH	Yes	Yes	3.5	5

Inh-B Inhibin B, TV testicular volume, T testosterone, CHH congenital hypogonadotropic hypogonadism, CPHD combined pituitary hormone deficiency.

^aMeasured during FSH + LH treatment, further increase as LH was replaced with T.

^bMean (SD) for pretreatment and treatment periods.

^cMicropenis is reported in this table based on penile lenght provided in the original article, if unequivocal (reference values: Boas et al., 2006).

^dPatient #1, only moderately responding to LH/FSH therapy, received im. T 100 mg/m2/every two weeks for 2 months.

^eNo individual data, only mean (SD) for patient series available.